Tuberculosis (TB) presents a serious healthcare crisis. In high burden, low resource countries, poor healthcare access, high cost, and laboratory dependence inhibits testing, leading to delays in diagnosis, increasing transmission and disease severity.  Development of affordable, sensitive and rapid diagnostic tools for diagnosis of TB may play a vital role in resource-poor settings, where the incidence of disease is high. The present study may reveal the expression patterns and/or validity of host biomarkers in whole blood of patients with PTB, EPTB, as well as in healthy controls, which may inform diagnostic test development. Development of host biomarker-based TB diagnostic kits may help clinicians to diagnose and monitor onset and progression of disease at an earlier stage and provide solutions where existing diagnostic options are inadequate. TB diagnostic kits developed from the output of the present study will improve both early diagnosis/triage and patient stratification and will be cost effective and specific. They may be considered an alternative for current diagnostic tests such as IGRA which lack sensitivity and are inadequate and/or expensive.